StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

NovoCure cash

Cash and short-term investments held at the end of each period.

NovoCure's cash was $96.73M at Sep 30, 2026. For fiscal 2025 it was $93.55M, down 43.7% from the year before. Over ten years it grew -2.4% a year on average. The highest annual figure on record is $246.17M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$93.55M-43.7%
FY2024Dec 31, 2024$166.09M-31.0%
FY2023Dec 31, 2023$240.82M+107.9%
FY2022Dec 31, 2022$115.83M-44.7%
FY2021Dec 31, 2021$209.61M-14.9%
FY2020Dec 31, 2020$246.17M+37.2%
FY2019Dec 31, 2019$179.42M+25.7%
FY2018Dec 31, 2018$142.76M+76.9%
FY2017Dec 31, 2017$80.72M-19.3%
FY2016Dec 31, 2016$100.05M-16.3%
FY2015Dec 31, 2015$119.51M+107.4%
FY2014Dec 31, 2014$57.61M-67.2%
FY2013Dec 31, 2013$175.89M+404.1%
FY2012Dec 31, 2012$34.89M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$96.73M-71.7%
Q2 FY2026Jun 30, 2026$103.62M-31.9%
Q1 FY2026Mar 31, 2026$97.32M-24.8%
Q4 FY2025Dec 31, 2025$93.55M-43.7%
Q3 FY2025Sep 30, 2025$342.12M+84.5%
Q2 FY2025Jun 30, 2025$152.13M-9.7%
Q1 FY2025Mar 31, 2025$129.43M-71.7%
Q4 FY2024Dec 31, 2024$166.09M-31.0%
Q3 FY2024Sep 30, 2024$185.42M+19.7%
Q2 FY2024Jun 30, 2024$168.44M+7.0%
Q1 FY2024Mar 31, 2024$457.36M+145.1%
Q4 FY2023Dec 31, 2023$240.82M+107.9%
Q3 FY2023Sep 30, 2023$154.86M-36.5%
Q2 FY2023Jun 30, 2023$157.49M-57.2%
Q1 FY2023Mar 31, 2023$186.64M-2.6%
Q4 FY2022Dec 31, 2022$115.83M-44.7%
Q3 FY2022Sep 30, 2022$243.81M-64.7%
Q2 FY2022Jun 30, 2022$367.76M+2.0%
Q1 FY2022Mar 31, 2022$191.63M-41.2%
Q4 FY2021Dec 31, 2021$209.61M-14.9%
Q3 FY2021Sep 30, 2021$690.69M+193.4%
Q2 FY2021Jun 30, 2021$360.59M+82.5%
Q1 FY2021Mar 31, 2021$325.98M+78.4%
Q4 FY2020Dec 31, 2020$246.17M+37.2%
Q3 FY2020Sep 30, 2020$235.38M+12.0%
Q2 FY2020Jun 30, 2020$197.59M+8.5%
Q1 FY2020Mar 31, 2020$182.71M+18.5%
Q4 FY2019Dec 31, 2019$179.42M+25.7%
Q3 FY2019Sep 30, 2019$210.17M+67.9%
Q2 FY2019Jun 30, 2019$182.18M+56.2%
Q1 FY2019Mar 31, 2019$154.16M+35.5%
Q4 FY2018Dec 31, 2018$142.76M+76.9%
Q3 FY2018Sep 30, 2018$125.16M+48.6%
Q2 FY2018Jun 30, 2018$116.63M+42.7%
Q1 FY2018Mar 31, 2018$113.76M+32.1%
Q4 FY2017Dec 31, 2017$80.72M-19.3%
Q3 FY2017Sep 30, 2017$84.23M–
Q2 FY2017Jun 30, 2017$81.73M–
Q1 FY2017Mar 31, 2017$86.12M–
Q4 FY2016Dec 31, 2016$100.05M–

More NovoCure figures

See a number that looks wrong?